Regorafenib in glioblastoma recurrence: A case report

Regorafenib in glioblastoma recurrence: A case report

GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response t...

Full description

Bibliographic Details
Main Authors: Beatrice Detti, Silvia Scoccianti, Sara Lucidi, Virginia Maragna, Maria Ausilia Teriaca, Michele Ganovelli, Isacco Desideri, Victoria Lorenzetti, Erika Scoccimarro, Daniela Greto, Lorenzo Livi
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Regorafenib
Glioblastoma recurrent
Malignant glioma
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220300988

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220300988

Similar Items